17 September 2019
News
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD) after a successful bid led by Eastern AHSN and Cambridge University Hospital Partners.
Cambridge, UK/MA, September 11 2019: o2h Discovery is pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock backed biotech company based in the Cambridge MA.
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
In the latest of a string of senior appointments, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has recruited Consultant Pharmaceutical Physician, Susan Tansey.
Dr Tansey joins Boyds with more than 20 years’ experience in rare disease clinical trials. A paediatrician specialising in respiratory paediatrics and neonatology, Susan joined the pharmaceutical industry in 1998 and has worked in clinical development across several therapeutic areas, including vaccine research.
Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
Sandwich, Kent, September 9 2019 – The Chairman of Discovery Park, a thriving high-quality science park playing a key role in the South East of England’s life sciences community, will be addressing important drivers in the development of the Park at a series of conferences in the Autumn. At events organized by CRACK IT, Life Sciences Integrates, and Cancer Research UK Martino Picardo is looking forward to talking about his experience in open innovation, pre-competitive collaboration and entrepreneurship.
Cambridge, UK, 9th September 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr. Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr. Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.
Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
Leading pharmaceutical and biotech product development consultancy Boyds has enhanced its clinical and medical affairs services offering following the acquisition of Blue Duck Consulting.
Since 2013, Blue Duck has provided expert preclinical and clinical drug development strategies and specialist monitoring and project management of clinical operations services in a range of therapeutic areas, led by its founder Dr Karen O’Hanlon, who joins Boyds as Director of Clinical Operations.
Cambridge, UK, 05 September, 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the introduction of a new ReCIVA® Breath Sampler and CASPERTM Portable Air Supply, designed to support internal biomarker discovery programs and those of academic and biopharma clients, and to measure levels of known volatile organic compounds (VOCs) on breath.